Literature DB >> 31049749

Invasive therapies for patients with concomitant heart failure and atrial fibrillation.

Wei Wei1,2, Michael Shehata3, Xunzhang Wang1,3, Fang Rao1,2,4, Xianzhan Zhan1,2, Huiming Guo1, Xianhong Fang1,2, Hongtao Liao1,2, Jian Liu1, Hai Deng1,2, Yang Liu1,2, Yumei Xue5,6, Shulin Wu7,8.   

Abstract

Atrial fibrillation (AF) and heart failure (HF) are two clinical entities that can present either separately or concurrently. One entity can lead to the other and vice versa as AF can not only be the underlying etiology of HF but also exacerbate HF due to other cardiac diseases. Besides prevention of cerebral and systemic embolism and elimination of AF-related symptoms, restoration of sinus rhythm for AF patients helps to avoid or reduce HF, irrespective of their underlying heart disease. Successful rates of medical therapy for AF are low in persistent AF, and much lower in long-standing AF, while invasive procedures for AF yield promising results. In this review, the authors evaluate the value of invasive therapies for HF patients complicated with non-valvular AF. We examine this clinical problem by interpreting the relationships between these two entities: the mechanism of tachycardia-induced cardiomyopathy (TIC), past opinions about rhythm control and rate control of AF, discrimination of HF-related AF and AF-induced HF, how to identify the AF patients that could benefit from invasive therapies, and how to select invasive therapies for different AF patients and peri-operative treatments.

Entities:  

Keywords:  Ablation; Atrial fibrillation; Heart failure; Invasive therapy; Medication

Mesh:

Year:  2019        PMID: 31049749     DOI: 10.1007/s10741-019-09795-0

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  72 in total

1.  Prognosis of atrial fibrillation in congestive heart failure.

Authors:  Johan R Folkeringa; H J G M Crijns; D J Van Veldhuisen
Journal:  Circulation       Date:  2004-01-20       Impact factor: 29.690

2.  Catheter ablation of atrial fibrillation in patients with severely impaired left ventricular systolic function.

Authors:  Ken Kato; Koichiro Ejima; Noritoshi Fukushima; Makoto Ishizawa; Osamu Wakisaka; Ryuta Henmi; Kentaro Yoshida; Toshiaki Nuki; Kotaro Arai; Bun Yashiro; Tetsuyuki Manaka; Kyomi Ashihara; Morio Shoda; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2015-01-30       Impact factor: 2.037

3.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

Authors:  Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld
Journal:  Europace       Date:  2016-08-27       Impact factor: 5.214

4.  Hybrid procedures for persistent atrial fibrillation: necessity and timing of the catheter ablation stage.

Authors:  Alan Bulava
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial).

Authors:  Ross J Hunter; Thomas J Berriman; Ihab Diab; Ravindu Kamdar; Laura Richmond; Victoria Baker; Farai Goromonzi; Vinit Sawhney; Edward Duncan; Stephen P Page; Waqas Ullah; Beth Unsworth; Jamil Mayet; Mehul Dhinoja; Mark J Earley; Simon Sporton; Richard J Schilling
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-01-01

6.  Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence.

Authors:  Shinya Suzuki; Koichi Sagara; Takayuki Otsuka; Shunsuke Matsuno; Ryuichi Funada; Tokuhisa Uejima; Yuji Oikawa; Akira Koike; Kazuyuki Nagashima; Hajime Kirigaya; Junji Yajima; Hitoshi Sawada; Tadanori Aizawa; Takeshi Yamashita
Journal:  Circ J       Date:  2011-12-08       Impact factor: 2.993

7.  Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: a prospective study.

Authors:  T Yamada; M Fukunami; T Shimonagata; K Kumagai; H Ogita; Y Asano; A Hirata; H Masatsugu; N Hoki
Journal:  J Am Coll Cardiol       Date:  2000-02       Impact factor: 24.094

8.  A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study).

Authors:  R J Shelton; A L Clark; K Goode; A S Rigby; T Houghton; G C Kaye; J G F Cleland
Journal:  Heart       Date:  2009-03-11       Impact factor: 5.994

Review 9.  Tachycardia-induced cardiomyopathy.

Authors:  Ernesto Umana; C Arturo Solares; Martin A Alpert
Journal:  Am J Med       Date:  2003-01       Impact factor: 4.965

Review 10.  Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate.

Authors:  L Di Lullo; A Bellasi; V Barbera; D Russo; L Russo; B Di Iorio; M Cozzolino; C Ronco
Journal:  Indian Heart J       Date:  2017-01-22
View more
  1 in total

1.  Exosomes from Bone Marrow Mesenchymal Stem Cells with Overexpressed Nrf2 Inhibit Cardiac Fibrosis in Rats with Atrial Fibrillation.

Authors:  Lijuan Xu; Yingchao Fan; Liting Wu; Cui Zhang; Min Chu; Yuan Wang; Wenfang Zhuang
Journal:  Cardiovasc Ther       Date:  2022-03-15       Impact factor: 3.023

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.